7.29
Analiza niekompartmentowa: Różne parametry farmakokinetyczne
Podejście niekompartmentowe jest szeroko stosowaną metodą w farmakokinetyce do oceny zachowań leków w organizmie. Bierze pod uwagę kilka czynników, w…
Podejście bezkompartmentowe wykorzystuje różne czynniki, w tym klirens, biodostępność i całkowitą objętość dystrybucji.
Po podaniu leku całkowity klirens leku można określić, dzieląc dawkę leku przez obszar pod krzywą stężenie-czas od zera do nieskończoności, jak uzyskano metodą trapezową.
Biodostępność, F, można określić na podstawie danych dotyczących stężenia leku po doustnym i dożylnym podaniu leku.
Całkowita objętość dystrybucji, Vss, jest iloczynem klirensu i średniego czasu przebywania.
Średni czas przebywania można łatwo obliczyć tylko po podaniu dożylnym pojedynczej dawki, co stanowi ograniczenie podejścia bezkompartmentowego w porównaniu z podejściem kompartmentowym.
View the full transcript and gain access to JoVE Core videos
Q1: How is total drug clearance calculated in noncompartmental analysis?
Total drug clearance is calculated by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's overall exposure in the body over time and is commonly determined using the trapezoidal method, a numerical integration technique that estimates this critical pharmacokinetic parameter.
Q2: What does bioavailability measure in drug administration?
Bioavailability, denoted as F, refers to the fraction of an administered dose that reaches the systemic circulation unchanged. It is determined by analyzing drug concentration data after both oral and intravenous administration, providing insights into how much of the drug is actually absorbed and available for therapeutic effect in the body.
Q3: How is the total volume of distribution calculated?
The total volume of distribution, represented as Vss, is calculated by multiplying the drug's clearance by the mean residence time. Mean residence time refers to the average time a drug molecule spends in the body, making this calculation essential for understanding how extensively a drug distributes throughout body tissues and fluids.
Q4: What is a key limitation of the noncompartmental approach?
The noncompartmental approach has a significant limitation in calculating mean residence time, which can only be readily determined after a single intravenous dose. This restriction distinguishes the noncompartmental approach from the compartmental approach, which allows greater flexibility in estimating pharmacokinetic parameters under various dosing scenarios.
Q5: Why is the trapezoidal method used in noncompartmental analysis?
The trapezoidal method is a numerical integration technique commonly employed to calculate the area under the concentration-time curve from zero to infinity. This method provides an accurate estimate of total drug exposure over time, which is essential for determining clearance and other critical pharmacokinetic parameters in the noncompartmental approach.
Q6: What factors does the noncompartmental approach consider when assessing drug behavior?
The noncompartmental approach utilizes three primary factors: clearance, bioavailability, and total volume of distribution. These parameters collectively assess how drugs are absorbed, distributed, and eliminated from the body, providing a comprehensive model-independent evaluation of drug behavior without requiring assumptions about specific compartmental structures.
Q7: How does the noncompartmental approach differ from the compartmental approach?
The noncompartmental approach is model-independent and does not assume specific body compartments, making it more flexible for various dosing scenarios. However, it cannot readily calculate mean residence time except after single intravenous doses, whereas the compartmental approach allows more flexibility in parameter estimation but requires assumptions about drug distribution into defined body compartments.